An from the horses mouht:

verfasst von Lullaby, 19.11.2000, 10:22

The net loss for the three months ended September 30, 2000 was $24,858,000 or $0.46 per basic and diluted share, compared to a net loss of $14,286,000 or $0.28
per basic and diluted share, for the same period in 1999. The net operating loss before debt conversion expense for the three months ended September 30, 2000 was
$10,483,000 or $0.19 per basic and diluted share.

Total revenues increased to $13,866,000 in the third quarter of 2000 from $7,225,000 in the third quarter of 1999. In the third quarter of 2000, royalty and product
sales revenue was $3,221,000 and collaborative and other research and development revenue was $10,645,000. In the third quarter of 1999, we recognized
$2,180,000 in royalties and product sales and $5,045,000 in collaborative and other research and development revenue.

Royalty and product sales revenue consists of Agenerase royalty revenue from Glaxo Wellcome as well as sales of commercial drug substance to Kissei
Pharmaceutical Co., Ltd. ("Kissei") in Japan in the third quarter of 2000. Agenerase royalty revenue is based upon worldwide net sales of Agenerase as provided by
Glaxo Wellcome.

The growth in collaborative and other research and development revenue in the third quarter of 2000, as compared with the third quarter of 1999, is principally due to a
new collaborative agreement with Novartis Pharma AG (Novartis) entered into in May of 2000. We recorded $6,591,000 in collaborative revenue from Novartis in the
third quarter of 2000 under the agreement. As of June 30, 2000, the research support payments from Kissei under the p38 MAP Kinase collaboration ended.

"Ended".

The
balance of collaborative and other research and development revenue for both 2000 and 1999 is made up of development reimbursements and research support
payments from other collaborative partners.

Total costs and expenses increased to $29,038,000 in the third quarter of 2000 from $23,563,000 in the third quarter of 1999. Royalties and product costs of
$1,147,000 and $727,000 in the third quarter of 2000 and 1999, respectively, consist of royalty payments to G.D. Searle on the sales of Agenerase as well as the cost
of commercial drug substance sold to Kissei in the third quarter of 2000. The increase in royalties and product costs is due primarily to increased royalties paid to G.D.
Searle.

"Increased".

Research and development expenses increased $4,927,000 during the three months ended September 30, 2000 as compared with same period in 1999. We continue to
expand our research and development operations both in the US and the UK. Related to our expansion were increases in personnel, facilities expenses, equipment
depreciation and increased technology license payments for access to gene database information.

"Increased expenses".

Additionally, there was an increase in development expenditures due
to increased development activities associated with our IMPDH inhibitor, VX-497, and our p38 MAP Kinase inhibitor, VX-745. We anticipate that research and
development expenses will increase as personnel are added and additional research and development activities are expanded to accommodate existing collaborations
and additional commitments we may undertake in the future.

"Will increase.""We may (not will) untertake".

Gruß

L. (kein undertaker!)


<center>

<HR>

</center>

Thread gesperrt

 

gesamter Thread:

• Topp, die Wette gilt - sumima, 18.11.2000, 21:31
  • Re: Topp, die Wette gilt - JüKü, 18.11.2000, 21:36
    • Re: Topp, die Wette gilt / ABER... - JüKü, 18.11.2000, 21:37
      • 90? (owT) - lentas, 18.11.2000, 21:39
    • Wetten das....? mkT - Das Orakel, 18.11.2000, 22:08
      • Re: Wetten das....? mkT - JüKü, 18.11.2000, 22:14
        • Re: Wetten das....? mkT - Das Orakel, 18.11.2000, 23:52
          • Re: Wetten das....? mkT - JüKü, 19.11.2000, 00:17
            • Erklärung.... - Das Orakel, 19.11.2000, 02:22
      • Re: Wetten das....? Vertex / Logo - Toni, 18.11.2000, 22:39
        • Re: Wetten das....? Vertex / Logo / Toni - JüKü, 18.11.2000, 22:55
          • Re: Vertex / Logo - peinlich - LOL - Toni, 18.11.2000, 23:19
            • Vertex - LogoAnalysen... - Das Orakel, 19.11.2000, 02:13
        • Vertex / Logo? LOL - Mitnichten.... - Das Orakel, 18.11.2000, 22:56
          • Re: Vertex / Logo? LOL - Mitnichten.... - JüKü, 18.11.2000, 23:09
            • Re: Vertex / Logo? LOL - Mitnichten.... - Das Orakel, 19.11.2000, 00:32
            • Re: Vertex / Logo? LOL - Mitnichten.... So, so... - Lullaby, 19.11.2000, 10:06
            • Re: Und auchn das, bittschön: - Lullaby, 19.11.2000, 10:14
            • An from the horses mouht: - Lullaby, 19.11.2000, 10:22
              • Re: @Orakel - Jetzt hat Dich der Lullaby auch grad noch"erschlagen" (owT) - Toni, 19.11.2000, 11:19
          • Re: Vertex / Logo? LOL - Mitnichten.... - Toni, 19.11.2000, 11:15
  • @sumima: Siemens-Kursdaten - Uwe, 18.11.2000, 22:29
    • @Uwe, danke - Import o.k., aber.-Konvertierung kapiere ich nicht - sumima, 18.11.2000, 22:48
      • Re: @Uwe, danke - Import o.k., aber.-Konvertierung kapiere ich nicht - Uwe, 18.11.2000, 23:54
    • @Uwe - Kursdaten - Sascha, 19.11.2000, 17:35
      • OI = Open Interest = Anzahl offener (ausstehender) Kontrakte (Fut./Opt. only)owT - Tobias, 19.11.2000, 17:43
  • Siemens - meine EW-Zählung lautet: - sumima, 19.11.2000, 20:04
    • Re: Siemens und andere - ASCII-Datenreihen: Kurse im Textformat - Uwe, 19.11.2000, 20:35